Nipro Corporation vs Terumo Corporation
Terumo holds the stronger position because it faces lighter rival pressure and posts far higher profit margins than Nipro, based on each company's most recent fiscal year results.
Nipro Corporation
Japanese maker of dialyzers, insulin needles, and glass vials for hospitals worldwide.
Terumo Corporation
Japanese medtech maker of cardiovascular devices, blood management systems and infusion pumps used in hospitals worldwide
Dimension by dimension
| Dimension | Nipro Corporation | Terumo Corporation |
|---|---|---|
| Staying power of the core product | Nipro's core products, dialysis machines and packaging lines, show some softness in its overall standing as of July 2026. | Terumo's core products, cardiovascular devices and pumps, show the stronger staying power of the two as of July 2026. |
| Exposure to AI absorbing the product | AI is unlikely to absorb Nipro's dialysis machines and packaging lines, given their hardware-dependent, regulated nature. | AI is similarly unlikely to absorb Terumo's cardiovascular devices and pumps, given their hardware-dependent, regulated nature. |
| How easily a giant could copy them | Nipro's manufacturing base and regulatory clearances make its dialysis and packaging business difficult for a new entrant to replicate quickly. | Terumo's manufacturing base and regulatory clearances make its cardiovascular device business equally difficult for a new entrant to replicate quickly. |
| Pressure from rivals | Nipro faces heavier direct pressure from rivals such as BD, Terumo, and Fresenius, though these peers coexist rather than take its share, as of July 2026. | Terumo faces lighter direct pressure from rivals, with no meaningful customer loss visible in the evidence, as of July 2026. |
| Depth of protection (moat) | Nipro's competitive protection is narrower, consistent with its lower FY2026 operating margin of 5.7% and smaller net profit of ¥13.5 billion. | Terumo's competitive protection is deeper, consistent with its higher FY2025 operating margin near 15.6% and larger operating profit of ¥176.3 billion. |
| Financial footing | Nipro posted FY2026 net sales of ¥660.5 billion with an operating margin of 5.7% and net profit of ¥13.5 billion. | Terumo posted FY2025 revenue of ¥1,131.9 billion with operating profit of ¥176.3 billion, an operating margin near 15.6%, and adjusted operating profit of ¥219.4 billion. |
Questions people ask
- Is Nipro or Terumo more exposed to AI replacing its products?
- Neither is exposed in a meaningful way. Both Nipro's dialysis and packaging lines and Terumo's cardiovascular and infusion devices are rated Unlikely to be absorbed by AI.
- Which company has stronger financials, Nipro or Terumo?
- Terumo is stronger financially. Its FY2025 revenue of ¥1,131.9 billion and operating margin near 15.6% to 19.4% far outpace Nipro's FY2026 revenue of ¥660.5 billion and 5.7% operating margin.
- Could a large competitor easily copy Nipro or Terumo?
- No, both are rated Blocked against a giant copying their business, meaning neither Nipro nor Terumo shows evidence of being easily replicated by a larger rival.